Baird analyst David Koning maintains Global Payments (NYSE:GPN) with a Outperform and lowers the price target from $192 to $144.
Baird Maintains Outperform on Albireo Pharma, Raises Price Target to $55
Baird analyst Brian Skorney maintains Albireo Pharma (NASDAQ:ALBO) with a Outperform and raises the price target from $43 to $55.